Exertional Dyspnoea Responses Reported in the Dyspnoea Challenge and Measures of Disease Severity in COPD
Overview
Authors
Affiliations
Background: The Dyspnoea Challenge has been developed to facilitate the field-based measure of exertional dyspnoea(ED). To further validate the test, we aimed to; investigate the relationship between end-exercise ED, generated by a fixed-intensity Dyspnoea Challenge(DC), and measures of disease severity (Forced expiratory volume in 1 s(FEV), six-minute walk distance(6MWD), breathing reserve(V̇/MVV), modified medical research council dyspnoea scale (mMRC), Body-mass index, airflow Obstruction, Dyspnoea, and Exercise (BODE index) and compare the physiological response of the DC to a six-minute walk test(6MWT).
Methods: Thirty-two individuals (15 female) with COPD (GOLD II-IV) (age: 69.7 ± 9.4 yrs; FEV: 49.1 ± 18.2 %) performed 2×6MWT and 2xDC at a treadmill speed of 3 km h and gradient of 4 %. The intensity of ED was measured using the modified Borg dyspnoea scale at baseline and end-exercise with heart rate (HR) and oxygen saturation (SO) monitored continuously. During 1×6MWT and 1xDC pulmonary gas exchange, cardiac output (Q̇) and dynamic hyperinflation were measured.
Results: End-exercise ED measured during the DC was not correlated to FEV, but moderately correlated to; 6MWD(r = -0.54, P < .01), V̇/MVV (r = 0.46, P = .02), mMRC(r = 0.45, P = .01), and the BODE index(r = 0.53, P < .01). When comparing the DC and 6MWT, participants walked to comparable levels of oxygen consumption(P = .38), ventilation(P = .37), Q̇(P = .20), V̇/MVV(P = .83), maximum HR percentages(P = .67) and dynamically hyperinflated to a similar degree(P = .37).
Conclusions: The Dyspnoea Challenge is correlated to different parameters of disease severity and produces a similar physiological and ED response to that of the 6MWT with the added benefit of being appropriate for longitudinal assessment of ED.
Palmer T, Obst S, Aitken C, Walsh J, Sabapathy S, Adams L Eur Respir Rev. 2023; 32(169).
PMID: 37558262 PMC: 10410401. DOI: 10.1183/16000617.0016-2023.
Aronson K, Jacobs S, Repola D, Swigris J BMJ Open Respir Res. 2023; 10(1).
PMID: 37419519 PMC: 10347448. DOI: 10.1136/bmjresp-2022-001546.